Abion Administers BarbaMakeup to Patients in Clinical Trials at MD Anderson in the US

Company States "Actively Discussing LO"
Clinicians Say "High Objective Response Rate and Safety"

Abion announced on the 8th that it has completed the first patient dosing in the Phase 2 clinical trial in the United States at the MD Anderson Cancer Center for its non-small cell lung cancer c-MET (hepatocyte growth factor receptor) mutation-targeted therapy, Babamekip (ABN401).

Babamekip is an anticancer drug targeting c-MET, the main resistance cause of Tagrisso. It is currently undergoing Phase 2 clinical trials in the United States, Korea, Taiwan, and other countries, including approval from the U.S. Food and Drug Administration (FDA). Interim results were announced last October, demonstrating efficacy and safety.

The interim results of the Phase 2 trial showed an ORR (objective response rate) of approximately 53%, with a 75% response rate in the treatment-naive patient group. This is a superior figure compared to competing drugs such as Novartis's Tabrecta and Merck's Tepmetko.

The University of Texas MD Anderson Cancer Center, designated in 1971 as one of the first comprehensive cancer treatment centers by the United Cancer Action Program, is the largest of its kind in the world. Abion plans to recruit U.S. MET (mesenchymal-epithelial transition factor) patients at the MD Anderson Cancer Center to advance its global clinical trials.

The company stated, "MET experts continue to praise the interim results," adding, "Based on these data, we are actively discussing license-out (LO) agreements with major global biotech companies."

Professor Xiuning Le, a newly participating clinical investigator in the Babamekip trial at the MD Anderson Cancer Center, also emphasized Babamekip's high objective response rate and safety on his X (formerly Twitter) account. Professor Le is an authority on MET research with prior experience participating in Tepmetko clinical trials.

An Abion representative explained, "With the start of U.S. patient enrollment, we are accelerating global clinical trials and plan to complete patient enrollment within this year," adding, "By successfully achieving clinical milestones, we have moved one step closer to technology export of our pipeline."

This content was produced with the assistance of AI translation services.